



STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES

APALUTAMIDE

Generic	Brand	HICL	GCN	Exception/Other
APALUTAMIDE	ERLEADA	44773		

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of metastatic castration-sensitive prostate cancer (mCSPC)?

If yes, continue to #3.

If no, continue to #2.

2. Does the patient have a diagnosis of non-metastatic castration-resistant prostate cancer (nmCRPC) **AND** meet the following criterion?

- The patient has high risk prostate cancer (i.e., rapidly increasing prostate specific antigen [PSA] levels)

If yes, continue to #3.

If no, do not approve.

DENIAL TEXT: See the denial text at the end of the guideline.

3. Has the patient previously received a bilateral orchiectomy?

If yes, **approve for 12 months by HICL with a quantity limit of #4 per day.**

If no, continue to #4.

4. Is the requested medication being used concurrently with a gonadotropin releasing hormone (GnRH) agonist or antagonist (i.e., leuprolide, goserelin, histrelin, degarelix)?

If yes, **approve for 12 months by HICL with a quantity limit of #4 per day.**

If no, do not approve.

INITIAL DENIAL TEXT: The guideline named **APALUTAMIDE (Erleada)** requires a diagnosis of metastatic castration-sensitive prostate cancer (mCSPC) or non-metastatic castration-resistant prostate cancer (nmCRPC). In addition, the requested medication must be used concurrently with a gonadotropin releasing hormone (GnRH) agonist or antagonist (i.e., leuprolide, goserelin, histrelin, degarelix), unless the patient has previously received a bilateral orchiectomy. In addition, the following criteria must be met:

For a diagnosis of non-metastatic castration-resistant prostate cancer, approval requires:

- The patient has high risk prostate cancer (i.e., rapidly increasing prostate specific antigen [PSA] levels)

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES

APALUTAMIDE

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

1. Does the patient have **ONE** of the following diagnoses?
 - Metastatic castration-sensitive prostate cancer (mCSPC)
 - Non-metastatic castration resistant prostate cancer (nmCRPC)

If yes, **approve for 12 months by HICL with a quantity limit of #4 per day.**

If no, do not approve.

RENEWAL DENIAL TEXT: The guideline named **APALUTAMIDE (Erleada)** requires a diagnosis of metastatic castration-sensitive prostate cancer (mCSPC) or non-metastatic castration resistant prostate cancer (nmCRPC).

RATIONALE

For further information, please refer to the prescribing information and/or drug monograph for Erleada.

REFERENCES

- Erleada [Prescribing Information]. Horsham, PA: Janssen. September 2019.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 01/01/20

Created: 05/18

Client Approval: 11/19

P&T Approval: 10/19